Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evogene ( (EVGN) ) has issued an update.
On April 21, 2025, Evogene Ltd. announced that Dead Sea Works Ltd., an affiliate of ICL Group Ltd., will acquire most of the activities of its subsidiary, Lavie Bio Ltd., for $15.25 million. Additionally, ICL will purchase Evogene’s MicroBoost AI Tech-Engine for agriculture for $3.5 million. This transaction, expected to close in the second quarter of 2025, involves transferring Lavie Bio’s core team, technology platform, microbial bank, and development programs to ICL. The acquisition marks a strategic move for Evogene to unlock asset value and is anticipated to significantly advance the global ag-biologicals field.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Underperform.
Evogene’s financial instability and negative cash flow are significant concerns, weighing heavily on its stock score. Technical analysis further indicates bearish trends. While earnings call insights show positive revenue growth and strategic partnerships, they are insufficient to offset the financial and valuation challenges, resulting in a low overall stock score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. is a computational biology company focused on revolutionizing the development of life-science-based products. It leverages cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene has established three technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focused on different core components such as microbes, small molecules, and genetic elements. The company develops products through its subsidiaries, including Lavie Bio Ltd., which focuses on ag-biologicals.
YTD Price Performance: -50.0%
Average Trading Volume: 21,047
Technical Sentiment Signal: Buy
Current Market Cap: $6.47M
See more data about EVGN stock on TipRanks’ Stock Analysis page.